Intracytoplasmic Morphologically Selected Sperm Injection and Advanced Maternal Age

Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) Benefits in the Presence of Advanced Maternal Age: a Prospective Randomized Study

The objective of this study was to evaluate the advanced maternal age as a rationale for performing intracytoplasmic morphologically selected sperm injection (IMSI).

This prospective randomized study included couples undergoing intracytoplasmic sperm injection (ICSI) as a result of advanced maternal age (≥ 37 years old). Couples were randomly allocated to receive one of two sperm selection procedures (ICSI, n = 33; or IMSI, n = 33). The groups were compared with regard to fertilization rate, percentage of high-quality embryos, implantation, pregnancy and miscarriage rates.

Inclusion Criteria:

• Good physical and mental health
• Advanced maternal age (≥ 37 years old)
• Regular menstrual cycles of 25-35 days
• Normal basal FSH and LH levels
• Body mass index less than 30 kg/m2
• Presence of both ovaries
• Intact uterus
• No hormone therapy for at least 60 days preceding the study

Exclusion Criteria:

• Polycystic ovaries
• Endometriosis
• Gynaecological/medical disorders
• Positive result in a screening for sexually transmitted diseases